PDF herunterladen
Thromb Haemost 2020; 120(01): 181-183
DOI: 10.1055/s-0039-1697956
Letter to the Editor
Georg Thieme Verlag KG Stuttgart · New York

Fibrin Clot Properties and Thrombin Generation in Hypertrophic Cardiomyopathy

Paweł Rubiś
1   Department of Cardiac and Vascular Diseases, Jagiellonian University Collegium Medicum, John Paul II Hospital, Kraków, Poland
2   Institute of Cardiology, Jagiellonian University Medical College, Jagiellonian University, Krakow, Poland
,
Joanna Natorska
2   Institute of Cardiology, Jagiellonian University Medical College, Jagiellonian University, Krakow, Poland
3   Krakow Center for Medical Research and Technology, John Paul II Hospital, Krakow, Poland
,
Michał Ząbczyk
2   Institute of Cardiology, Jagiellonian University Medical College, Jagiellonian University, Krakow, Poland
3   Krakow Center for Medical Research and Technology, John Paul II Hospital, Krakow, Poland
,
Ewa Dziewięcka
1   Department of Cardiac and Vascular Diseases, Jagiellonian University Collegium Medicum, John Paul II Hospital, Kraków, Poland
,
Aleksandra Karabinowska
1   Department of Cardiac and Vascular Diseases, Jagiellonian University Collegium Medicum, John Paul II Hospital, Kraków, Poland
,
Sylwia Wiśniowska-Śmiałek
1   Department of Cardiac and Vascular Diseases, Jagiellonian University Collegium Medicum, John Paul II Hospital, Kraków, Poland
,
Ann C. Garlitski
4   New England Cardiac Arrhythmia Center, Tufts Medical Center Boston, Massachusetts, United States
,
Piotr Podolec
1   Department of Cardiac and Vascular Diseases, Jagiellonian University Collegium Medicum, John Paul II Hospital, Kraków, Poland
2   Institute of Cardiology, Jagiellonian University Medical College, Jagiellonian University, Krakow, Poland
,
Anetta Undas
2   Institute of Cardiology, Jagiellonian University Medical College, Jagiellonian University, Krakow, Poland
3   Krakow Center for Medical Research and Technology, John Paul II Hospital, Krakow, Poland
› Institutsangaben Funding This work was supported by the Department of Scientific Research and Structural Funds of Medical College, Jagiellonian University (grant K/ZDS/007912).
Weitere Informationen

Publikationsverlauf

08. August 2019

21. August 2019

Publikationsdatum:
28. Oktober 2019 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Introduction

Although most patients with hypertrophic cardiomyopathy (HCM) are oligosymptomatic with normal life expectancy, approximately one-fifth experience increased morbidity and mortality.[1] There are a wide range of clinical manifestations of HCM including diastolic dysfunction, end-stage heart failure (HF), ischemia, left ventricular outflow tract (LVOT) obstruction, atrial fibrillation (AF), syncope, and sudden cardiac death (SCD). Thromboembolic (TE) events such as stroke are observed predominantly in patients with AF.[1] [2] In a landmark study, TE complications were reported in 51 (6%) out of 900 ambulatory HCM patients over a period of 7 ± 7 years with an overall incidence of 0.8%/year and 1.9% for those > 60 years old. The independent predictors of TE complications were found to be AF, age, and HF. Of note, in 6 (12%) patients with TE complications, the etiology was not established.[3]

Hypercoagulation has been demonstrated previously in HCM. However, blood coagulopathies in HCM patients have been poorly explored.[4] An unfavorable fibrin clot phenotype, including the formation of dense and poorly lysable clots, has been reported in patients with TE events.[5] Prothrombotic features have been demonstrated in AF patients with an increased risk of stroke.[6] It is unknown whether HCM per se predisposes to a prothrombotic state. We investigated fibrin clotting properties and thrombin generation parameters in HCM patients without concomitant AF.

 

  • References

  • 1 Elliott PM, Anastasakis A, Borger MA. , et al; Authors/Task Force members. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35 (39) 2733-2779
    CrossrefPubMedSuche in Google Scholar
  • 2 Olivotto I, d'Amati G, Basso C. , et al. Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. Cardiovasc Res 2015; 105 (04) 409-423
    CrossrefPubMedSuche in Google Scholar
  • 3 Maron BJ, Olivotto I, Bellone P. , et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39 (02) 301-307
    PubMedSuche in Google Scholar
  • 4 Dimitrow PP, Undas A, Bober M, Tracz W, Dubiel JS. Obstructive hypertrophic cardiomyopathy is associated with enhanced thrombin generation and platelet activation. Heart 2008; 94 (06) e21
    CrossrefPubMedSuche in Google Scholar
  • 5 Ząbczyk M, Undas A. Plasma fibrin clot structure and thromboembolism: clinical implications. Pol Arch Intern Med 2017; 127 (12) 873-881
    CrossrefPubMedSuche in Google Scholar
  • 6 Drabik L, Wołkow P, Undas A. Fibrin clot permeability as a predictor of stroke and bleeding in anticoagulated patients with atrial fibrillation. Stroke 2017; 48 (10) 2716-2722
    CrossrefPubMedSuche in Google Scholar
  • 7 Mills JD, Ariëns RA, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106 (15) 1938-1942
    CrossrefPubMedSuche in Google Scholar
  • 8 Carr Jr ME, Shen LL, Hermans J. Mass-length ratio of fibrin fibers from gel permeation and light scattering. Biopolymers 1977; 16 (01) 1-15
    CrossrefPubMedSuche in Google Scholar
  • 9 Sjøland JA. A new optimized method for the determination of fibrin clot permeability. Blood Coagul Fibrinolysis 2005; 16 (08) 579-583
    CrossrefPubMedSuche in Google Scholar
  • 10 Pieters M, Philippou H, Undas A, de Lange Z, Rijken DC, Mutch NJ. ; Subcommittee on Factor XIII and Fibrinogen, and the Subcommittee on Fibrinolysis. An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16 (05) 1007-1012
    CrossrefPubMedSuche in Google Scholar
  • 11 Hemker HC. Thrombin generation in a reconstituted system: a comment. Thromb Haemost 2002; 87 (03) 551-554
    Thieme ConnectPubMedSuche in Google Scholar
  • 12 Jung H, Yang PS, Sung JH. , et al. Hypertrophic cardiomyopathy in patients with atrial fibrillation: prevalence and associated stroke risks in a nationwide cohort study. Thromb Haemost 2019; 119 (02) 285-293
    Thieme ConnectPubMedSuche in Google Scholar
  • 13 Zabczyk M, Plens K, Wojtowicz W, Undas A. Prothrombotic fibrin clot phenotype is associated with recurrent pulmonary embolism after discontinuation of anticoagulant therapy. Arterioscler Thromb Vasc Biol 2017; 37 (02) 365-373
    CrossrefPubMedSuche in Google Scholar
  • 14 Cieslik J, Mrozinska S, Broniatowska E, Undas A. Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: a cohort study. Blood 2018; 131 (07) 797-807
    CrossrefPubMedSuche in Google Scholar